Repare Therapeutics Inc. (NASDAQ:RPTX) is MPM Asset Management LLC's 6th Largest Position

MPM Asset Management LLC cut its position in Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,683,707 shares of the company's stock after selling 558,929 shares during the period. Repare Therapeutics accounts for approximately 1.8% of MPM Asset Management LLC's investment portfolio, making the stock its 6th biggest holding. MPM Asset Management LLC owned about 3.96% of Repare Therapeutics worth $2,206,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RPTX. Barclays PLC lifted its position in Repare Therapeutics by 1,471.7% in the 3rd quarter. Barclays PLC now owns 8,330 shares of the company's stock valued at $29,000 after acquiring an additional 7,800 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Repare Therapeutics by 204.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after purchasing an additional 23,127 shares during the last quarter. Vontobel Holding Ltd. boosted its position in shares of Repare Therapeutics by 45.8% during the fourth quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company's stock valued at $46,000 after buying an additional 11,000 shares during the last quarter. Lynx1 Capital Management LP bought a new stake in Repare Therapeutics during the fourth quarter worth $104,000. Finally, JPMorgan Chase & Co. raised its position in Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock valued at $112,000 after buying an additional 85,798 shares during the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Stock Up 1.5%

RPTX stock traded up $0.02 during trading on Monday, reaching $1.36. The stock had a trading volume of 67,913 shares, compared to its average volume of 259,976. Repare Therapeutics Inc. has a one year low of $0.89 and a one year high of $4.29. The company's 50 day moving average is $1.17 and its two-hundred day moving average is $1.66. The company has a market capitalization of $58.33 million, a price-to-earnings ratio of -0.68 and a beta of 0.85.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. As a group, research analysts predict that Repare Therapeutics Inc. will post -2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price objective on Repare Therapeutics from $10.00 to $5.00 and set a "buy" rating on the stock in a research note on Friday, March 7th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.